Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders

Area of Science:

• Immunology
• Infectious Diseases
• Cell Therapy

Background:

• Primary immunodeficiency disorders (PIDDs) increase susceptibility to severe, potentially fatal viral infections.
• Impaired T-cell function is a primary cause of viral vulnerability in PIDD patients.
• Hematopoietic stem cell transplantation (HSCT) is a common treatment setting for PIDDs.

Purpose of the Study:

• To review the clinical experience and outcomes of virus-specific T-cell (VST) therapy for PIDD patients.
• To explore the expanding range of targeted viral pathogens in VST therapy.
• To discuss the potential of banked, third-party VSTs for broader access and improved treatment.

Main Methods:

• Review of clinical trials and case studies involving VST adoptive immunotherapy.
• Analysis of VST strategies targeting common viral pathogens like cytomegalovirus, EBV, and adenovirus.
• Evaluation of banked VST products from unrelated donors.

Main Results:

• VST therapy has demonstrated efficacy in combating viral infections post-HSCT in PIDD patients.
• Trials have evolved to target a wider array of viruses beyond traditional targets.
• Banked VSTs show promise for increasing accessibility to this specialized treatment.

Conclusions:

• Adoptive immunotherapy with VSTs is a valuable strategy for managing viral infections in PIDDs.
• Continued research into novel targets and donor sources will enhance VST therapy's clinical utility.
• VSTs hold significant potential for improving long-term outcomes in this vulnerable patient population.